Summary The Global Alzheimer's Disease Drug market is estimated to reach 3.3 Billion USD in 2017. The objective of report is to define, segment, and project the market on the basis of type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc. Based on products type, the report describes major products type share of regional market. Products mentioned as follows: By Type Donepezil Memantine Rivastigmine Based on region, the report describes major regions market by products and application. Regions mentioned as follows: Europe North America China Japan & Korea Based on Application, the report describes major Application share of regional market. Application mentioned as follows: Early to Moderate Stages Moderate to Severe Stages Leading vendors in the market are included based on profile, business performance etc. Vendors mentioned as follows: Allergan Eisai Novartis Daiichi Sankyo Merz Pharma Pfizer Johnson & Johnson Lundbeck
Table of Contents 1 Market Overview 1.1 Objectives of Research 1.1.1 Definition 1.1.2 Specifications 1.2 Market Segment 1.2.1 by Type 1.2.1.1 Donepezil 1.2.1.2 Memantine 1.2.1.3 Rivastigmine 1.2.2 by Application 1.2.2.1 Early to Moderate Stages 1.2.2.2 Moderate to Severe Stages 1.2.3 by Regi
